Published On: Tue, Sep 20th, 2016

Applied Genetic Technologies Corp. (AGTC) – Investment Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Applied Genetic Technologies Corp. (NASDAQ: AGTC) recently:

9/13/2016 – Applied Genetic Technologies Corp. had its price target lowered by analysts at Wedbush from $36.00 to $20.00. They now have an “outperform” rating on the stock.
9/13/2016 – Applied Genetic Technologies Corp. had its price target lowered by analysts at Stifel Nicolaus from $29.00 to $24.00. They now have a “buy” rating on the stock.
9/13/2016 – Applied Genetic Technologies Corp. was downgraded by analysts at Janney Montgomery Scott from a “buy” rating to a “sell” rating. They now have a $11.00 price target on the stock, down previously from $23.00.
9/13/2016 – Applied Genetic Technologies Corp. was downgraded by analysts at Wells Fargo & Co. from an “outperform” rating to a “market perform” rating.
9/13/2016 – Applied Genetic Technologies Corp. was downgraded by analysts at Cantor Fitzgerald from a “buy” rating to a “hold” rating. They now have a $15.00 price target on the stock, down previously from $32.00.
9/13/2016 – Applied Genetic Technologies Corp. had its price target lowered by analysts at BMO Capital Markets from $25.00 to $20.00. They now have an “outperform” rating on the stock.
9/13/2016 – Applied Genetic Technologies Corp. was downgraded by analysts at Roth Capital from a “buy” rating to a “neutral” rating. They now have a $12.00 price target on the stock, down previously from $34.00.

Applied Genetic Technologies Corp. (NASDAQ:AGTC) opened at 8.58 on Tuesday. The firm’s 50 day moving average price is $13.46 and its 200-day moving average price is $14.81. Applied Genetic Technologies Corp. has a 1-year low of $8.50 and a 1-year high of $21.43. The stock’s market cap is $154.89 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/applied-genetic-technologies-corp-agtc-investment-analysts-weekly-ratings-updates.html

Applied Genetic Technologies Corp. (NASDAQ:AGTC) last issued its earnings results on Monday, September 12th. The company reported $0.15 EPS for the quarter, beating the Zacks’ consensus estimate of $0.07 by $0.08. Applied Genetic Technologies Corp. had a negative net margin of 2.92% and a negative return on equity of 1.34%. The business had revenue of $12.10 million for the quarter. During the same period in the prior year, the business posted ($0.48) EPS. The business’s revenue was up 1604.2% on a year-over-year basis. On average, equities analysts anticipate that Applied Genetic Technologies Corp. will post ($0.61) earnings per share for the current year.
Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1), a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis, an inherited condition causing early blindness.

Receive News & Ratings for Applied Genetic Technologies Corp Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Applied Genetic Technologies Corp and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>